Skip to main content
. 2020 Aug 1;2020:8364247. doi: 10.1155/2020/8364247

Table 1.

Baseline characteristics of patients.

Survivors Nonsurvivors Control P value
n = 35 n = 36 n = 17
APACHE-II score 19.0 (13.0-25.0) 26.0 (20.0-32.0) <0.001a
SOFA score 9.0 (6.0-11.0) 13.0 (10.0-15.0) <0.001a
Procalcitonin (ng/L) 2.9 (0.5-12.9) 13.1 (2.8-33.0) 0.009a
C-reactive protein (mg/L) 169.0 (87.8-302.5) 178.6 (98.9-283.1) 1.2 (0.4-1.9) 1.00a
<0.001b,c
White blood cells (103/μL) 15.0 (11.0-21.8) 15.1 (10.7-21.2) 0.875a
Haemoglobin (g/dL) 10.2 (8.2-11.6) 9.5 (8.6-10.7) 0.945a
Fibrinogen (g/L) 5.2 (4.1-6.5) 5.2 (2.9-5.7) 0.279a
pFN (mg/L) 152.8 (114.5-164.2) 106.0 (63.7-149.4) 231.2 (191.2-273.2) 0.004a
<0.001b,c
EDA-FN (mg/L) 6.7 (3.8-20.5) 9.4 (2.6-20.3) 1.4 (0.9-1.6) 1.00a
<0.001b,c
ICU free days to day 28 18 (9–21) 20 (9–24) 0.103a

APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; pFN: plasma fibronectin; EDA-FN: extra domain A fibronectin; ICU: intensive care unit. The comparison of continuous variables between two independent groups (nonsurvivors vs. survivors) was performed using the Mann-Whitney U test. The comparison of continuous variables across three groups (nonsurvivors, survivors, control) was performed using the Kruskal-Wallis test, and a post hoc was used to compare subgroups. The P value represents statistically significant differences calculated between the following groups: anonsurvivors vs. survivors, bnonsurvivors vs. control, csurvivors vs. control.